The COVID-19 pandemic raises new challenges for the healthcare and pharmaceutical industries and special rules were adopted at various levels of legislation in this connection, which should be borne in mind by market players. The new rules raise monitoring and prevention tools, seek to facilitate the distribution of medicines, introduce certain price controls, provides for certain import duty and VAT exemptions, provides for tougher sanction for specific criminal and administrative offences, and relax a number of administrative and, to a limited extent, safety requirements…
